Baker McKenzie advises Vicore Pharma on USD 48 million directed share issue

"Baker McKenzie advised Vicore Pharma on a directed new share issue of approximately USD 48 million conducted by accelerated bookbuilding. Jefferies GmbH and Pareto Securities AB acted as Joint Global Coordinators and Joint Bookrunners, and Cantor Fitzgerald & Co. acted as Joint Bookrunner."

Baker McKenzie acted as legal advisor to Vicore Pharma in the transaction, while Jefferies GmbH and Pareto Securities AB served as Joint Global Coordinators and Joint Bookrunners and Cantor Fitzgerald & Co. acted as Joint Bookrunner. Vicore Pharma Holding AB carried out a directed new share issue of shares of approximately USD 48 million. The subscription price for the placement was set through an accelerated bookbuilding procedure. Vicore Pharma Holding AB is a clinical-stage pharmaceutical company developing a new class of disease-modifying drugs for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designations from the US Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. The company is publicly listed on Nasdaq Stockholm (VICO). Baker McKenzie represented Vicore Pharma with a team composed by: Henric Roth, Olof Larsson and Thea Hanson in Stockholm, and Adam Farlow and Charles Farnsworth in London.

Baker McKenzie advises Vicore Pharma on USD 48 million directed share issue

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads